A Randomized Controlled Clinical trial to evaluate the effect of Guggulvadi Churna in the management of Primary Hypothyroidism
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- reduction in tsh and Ft4 levels
研究概览
简要总结
Hypothyroidism is a clinical hypometabolic state which is defined by Low levels of TSH and High FT4.
It is characterised by Low metabolic rate, Hairloss, Slowened thinking capacity, weight gain.
.On the basis of symptomatology, hypothyroidism can also be established parallel to Medoroga. In Medoroga, all the channels that continuously supply nutrients to other tissues are blocked by Medas. So, further tissues
are not properly formed and only Medas is accumulated. Therefore, the patient becomes weak
and will be unable to perform any type of function
Guggulvadi Churna containing Shuddha Guggulu, Hareetaki, Vibheetaki, Amalaki, Shunti, Pippali, Maricha, Chitrakamula, Musta,Vidanga, and is indicated in Medo Vikara, Shleshma Vikaras, Madatyayam. This formulation
has Katu, Kashaya Rasa, Laghu- Ruksha Guna, Ushna Virya, Katu Vipaka, Kapha Vata
Pradhana Tridoshahara in nature. Deepana, Pachana property of the Guggulvadi Churna
helps to rekindle the suppressed Jatharagni. This Churna having Medo-Dhatwagni Vardaka
action can be highly target specific and effective in Medoroga. In-vitro and animal studies
have proven that Guggulu has thyroid stimulating activity
Some of the drugs of this Churna contains Lekhana property which helps to remove excess of Medas and Kapha obstructing the Srotases. Guggulu & Triphala being two of the ingredients, this formulation also exhibits
Rasayana property.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 60.00 Year(s)(—)
- 性别
- All
入选标准
- •TSH with in the range of 4.6 to 40 mU L FT4 less than 0.9 ng dL Anti-TPO less than 9 IU L.
排除标准
- •Low TSH, low FT4 Patients under medications such as Levothyroxine, Amiodarone, Birth control pills.
- •Patient who underwent thyroidectomy Grade 2 and 3 goitre K/C/O.
- •Hypertension Pregnant and lactating women.
结局指标
主要结局
reduction in tsh and Ft4 levels
时间窗: 46 days
次要结局
未报告次要终点
研究者
Dr Amirtha Lakshmi T
Sri Jayendra Saraswathi Ayurveda College & Hospital
